CYCLOSPORIN A IN RHEUMATOID ARTHRITIS

每日口服环孢菌素A（CSA）治疗慢性乙型肝炎的疗效和毒性 重度难治性类风湿性关节炎患者 正在进行一项为期6个月的低剂量双盲研究， (lmg/kg/天）与高剂量（10 mg/kg/天）CSA的比较。 患者 在6天后，疾病活动性改善40%或更高 药物治疗的几个月的选择继续CSA， 额外的6个月。 CSA对各种措施的影响 外周血中T淋巴细胞功能的变化。 在过去的一年中，分析了药代动力学研究和 CSA的免疫作用和12个月的临床试验 已完成并在科学会议上提出。 的 详细介绍试验临床结果的手稿已被 完成并接受出版。

The efficacy and toxicity of daily, oral cyclosporin A (CSA) in patients with severe, treatment-refractory rheumatoid arthritis is being evaluated in a 6 month double-blind study of low dose (lmg/kg/day) versus high dose (lOmg/kg/day) CSA. Patients with a 40%, or greater, improvement in disease activity following 6 months of drug therapy are given the option to continue CSA for an additional 6 months. The effects of CSA on various measures of T lymphocyte function in peripheral blood is being investigated. During the past year, analysis of pharmacokinetic studies and immunologic effects of CSA and the 12 months clinical trial have been completed and presented at scientific meetings. The manuscript detailing the clinical results of the trial has been completed and accepted for publication.